PMID- 23661232
OWN - NLM
STAT- MEDLINE
DCOM- 20140313
LR  - 20220408
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
VI  - 386
IP  - 9
DP  - 2013 Sep
TI  - Inhibitory effects of resveratrol on MCP-1, IL-6, and IL-8 production in human 
      coronary artery smooth muscle cells.
PG  - 835-9
LID - 10.1007/s00210-013-0877-9 [doi]
AB  - Resveratrol, a representative polyphenol compound, is known to have 
      antiatherogenic effects through its various actions including an 
      anti-inflammatory action. The processes of initiation and progression of 
      atherosclerosis are mediated by proinflammatory cytokines. The aim of this study 
      was to determine whether resveratrol affects cytokine production in human 
      coronary artery smooth muscle cells (HCASMCs). Each cytokine concentration in the 
      culture medium of HCASMCs was measured by flow cytometry using the cytometric 
      bead array system, and extracellular signal-regulated kinase (ERK) activity was 
      evaluated by Western blotting. Basal levels of monocyte chemoattractant protein-1 
      (MCP-1), interleukin (IL)-6, and IL-8 were significantly decreased in the 
      presence of resveratrol at 1-50 muM in a concentration-dependent manner and were 
      significantly decreased in the presence of U0126, an ERK inhibitor. Resveratrol 
      significantly decreased both basal and interferon-gamma (IFN-gamma) 
      (200 ng/ml)-stimulated levels of MCP-1, IL-6, and IL-8 and significantly 
      attenuated both basal and IFN-gamma-stimulated activity of ERK. TNF-alpha, IL-1beta, IL-10, 
      and IL-12p70 were detected only as trace levels in the culture medium with or 
      without IFN-gamma. Therefore, resveratrol is thought to inhibit production of MCP-1, 
      IL-6, and IL-8 in HCASMCs through attenuating ERK activity. Inhibition of 
      cytokine production in coronary artery smooth muscle cells may in part explain 
      antiatherogenic action of resveratrol.
FAU - Wakabayashi, Ichiro
AU  - Wakabayashi I
AD  - Department of Environmental and Preventive Medicine, Hyogo College of Medicine, 
      Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan. wakabaya@hyo-med.ac.jp
FAU - Takeda, Yuji
AU  - Takeda Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130510
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cytokines)
RN  - 0 (Stilbenes)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Cells, Cultured
MH  - Coronary Vessels/*cytology
MH  - Cytokines/*antagonists & inhibitors/metabolism
MH  - Extracellular Signal-Regulated MAP Kinases/*antagonists & inhibitors/metabolism
MH  - Humans
MH  - Myocytes, Smooth Muscle/*drug effects/metabolism
MH  - Resveratrol
MH  - Stilbenes/*pharmacology
EDAT- 2013/05/11 06:00
MHDA- 2014/03/14 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/17 00:00 [received]
PHST- 2013/04/17 00:00 [accepted]
PHST- 2013/05/11 06:00 [entrez]
PHST- 2013/05/11 06:00 [pubmed]
PHST- 2014/03/14 06:00 [medline]
AID - 10.1007/s00210-013-0877-9 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2013 Sep;386(9):835-9. doi: 
      10.1007/s00210-013-0877-9. Epub 2013 May 10.